Spectranetics' ThromCat XT
This article was originally published in The Gray Sheet
Executive Summary
Firm's "next-generation" thrombus removal system debuts in Europe following receipt of CE mark approval, announced June 23. The single-use, disposable device, which helps remove thrombus from native coronary arteries and infra-inguinal arteries, offers enhanced thrombus removal and ease-of-use over the current ThromCat, the company explains. The European approval triggered a $1.5 million milestone payment to Kensey Nash under the terms of a previous development and regulatory services agreement, Spectranetics notes